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ABSTRACT
INTRODUCTION: Myrtenal, a component of many plants’ essential oils, is a bicyclic monoterpenoid. Nu-
merous effects of myrtenal in experimental animals have been found – bronchodilatory, anti-inflammato-
ry, anti-aggregative and antihemolytic (in vitro), and antibacterial. Its other activities have been studied – 
antioxidant, antitumor, antihyperglycemic, vasodilating, heart rate reducing and hypotensive. Myrtenal is 
relatively little studied in the field of neuroscience. 
AIM: The aim of this article is to summarize the available information on the established biological activi-
ty of the monoterpenoid myrtenal.
MATERIALS AND METHODS: Scientific databases such as PubMed, ResearchGate, HMDB and others 
have been used to provide information on the published results of properties and activities of the test sub-
stance (myrtenal) over a period of 15 years (2003 – 2018). 
RESULTS: Our research confirmed the available data for its central nervous system (CNS) activity – anxio-
lytic and potentiating the effects of the hypnotic drugs, as well as the antioxidant properties. We have eval-
uated the neuromodulatory activity of M in brain tissue manifested in elevated levels of major neurotrans-
mitters in healthy rodents and those with neurodegenerative changes accompanied by improvement in the 
animals’ memory. 
CONCLUSION: Significant protective effects of myrtenal on neurodegenerative processes were estab-
lished. Probably they are related to its complex mechanisms, including neuromodulatory and antioxidant 
properties.
Keywords: myrtenal, biological activity, neurodegeneration
INTRODUCTION
The study of biologically active substances as 
promising agents for the therapy and prevention of 
multiple diseases is an important trend in modern 
experimental science. 
Terpenoids are a huge group of substances iso-
lated from plant volatile oils. A natural product called 
terpene was found in the pine resin in 1818. The Ger-
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specific mechanism, its other mechanisms of action 
continue to be the subject of discussion (5). Noncom-
petitive receptor inhibition is characteristic of the 
interaction of linalool with N-methyl-D-aspartate 
(NMDA) receptors (6) as well as that of borneol with 
N-cholinergic receptors (7).
In vitro and in vivo studies have revealed the 
effects of monoterpenes in diabetes, insulin resis-
tance and obesity (8). In vitro studies on various cell 
lines (including pancreatic β cells, muscle, adipo-
cyte and hepatic cells) revealed that besides carva-
crol and thymol that have a phenolic skeleton, most 
monoterpenes do not have the properties of direct 
radical scavengers due to their antidiabetic effects. 
Many natural flavonoids and polyphenols inhib-
it α-amylase and α-glucosidase at low (micromolar) 
concentrations but are of no therapeutic significance 
(9,10). Various experiments confirm that monoter-
penes effectively increase glucose utilization by in-
fluencing a glucose transporter (GLUT4) with the 
participation of some key pharmacological targets at 
the molecular level, including the insulin signaling 
pathway. Genipin and geniposide, as well as the iri-
doids and their glycosides exhibit antidiabetic prop-
erties in vitro. Geniposide stimulates insulin secre-
tion by activating the glucagon-like-1 receptor (11). 
Monoterpenes show promising antidiabetic effect in 
vivo (12) - elevation of liver glycogen levels (one of 
the main targets for antidiabetic drugs) was observed 
for borneol, citronellol and myrtenal. Carvacrol, car-
vone, citronellol, geniposide, myrtenal и paeoniflo-
rin modulate key liver enzymes of glucose metabo-
lism and decrease the activity of glucokinase and glu-
cose-6-phosphate dehydrogenase.
The role of inflammation as a link between di-
abetes and obesity has been established (13). Many 
monoterpenes exhibit ameliorative effects in inflam-
matory conditions associated with diabetes. By in-
fluencing key enzymes for the synthesis of fatty ac-
ids (acetyl-CoA carboxylase and synthase) in in vitro 
studies the direct improving effect of monoterpenes 
on lipid profile has been reported (14). 
The analgesic effect of many plant essential oils 
rich in monoterpenes has been established experi-
mentally (15).
Positive effects as radiotherapy supplementa-
tion of cancer diseases are observed in some mono-
man chemist Otto Wallach defined the structure of 
the terpenes in 1877. They are produced by many 
bacteria, fungi, plants and animals and have an im-
portant biological role.
Many of the essential oils have been used in folk 
medicine as cures, as well as perfumes and fragranc-
es long before their study began.  Some of their com-
ponents have biological activity and are used as med-
icines. Such substances are the taxanes (with anti-
tumor activity), artemisin (with antimalarial activ-
ity), etc. The study of this large group of substances 
with a complex mechanism of action, many of which 
show anti-inflammatory, antibacterial or antiviral 
activity, as potential pharmaceutical agents contin-
ues in various fields of medicine (1). Some terpenes 
have shown potential effects in Alzheimer‘s disease 
(2) - ginsenosides, ginkgolides, and cannabinoids 
have shown promising results in in vitro and in vivo 
studies. Oleanolic acid, ursolic acid and many others 
are also studied. The mechanisms of action are dif-
ferent – affecting acetylcholinesterase activity, reduc-
ing Аβ-aggregation, reducing oxidative stress in vari-
ous ways, etc. 
Monoterpenes, as components of essential oils, 
are plants’ secondary metabolites. They have vari-
ous pharmacological properties, including antifun-
gal, antibacterial, antioxidant, anticancer, spasmo-
lytic, hypotensive and vasodilating activity. The gen-
eral mechanism of action of monoterpenes, such as 
their antimicrobial and antitussive activity, is main-
ly related to their volatility. They have good distribu-
tion, pass through membrane barriers and interact 
with different biomolecules, assuming their action is 
non-specific and lacking activity against certain re-
ceptors in the body. Non-specific and noncompeti-
tive mechanism of action in the muscle-relaxing ef-
fect of some monoterpenes has been established (car-
vacrol) (3). Their hydrophobicity, as well as the essen-
tial oils as a whole, determine their effect on bacteri-
al cell structures (e.g., cell membrane) with a subse-
quent antimicrobial effect (4). 
Biological Effects and Specific Mechanisms of 
Action of Monoterpenes
Specific effects of monoterpenes on receptors 
have also been reported, such as the cooling effect 
of menthol by modulating the thermoreceptors. Al-
though its effects as a nasal decongestant have no 
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terpenes. They act as „radiosensitizers“ - increase in 
vitro the sensitivity of cancer cells (head and neck tu-
mors) to radiation therapy with subsequent induc-
tion of apoptosis (16). 
Memory-enhancing effects for some of the in-
vestigated monoterpenes – thymol (17) and carvacrol 
(18), by influencing different mechanisms have also 
been reported. Some of the bicyclic monoterpenoids 
suppress the acetylcholinesterase activity, which is 
increased in patients with Alzheimer’s disease. In a 
study of 17 representatives of these substances, (+) - 
and (-) - α-pinene and (+) - 3-carne appeared as po-
tent inhibitors of the enzyme, while the bicyclic ke-
tones and alcohols were weak (19).
AIM
The aim of this work is to summarize the avail-
able information on the established biological activ-
ity of the monoterpenoid Myrtenal in the literature.
Myrtenal ((−)-Myrtenal, (1R)-2-Pinen-10-al, 
(1R)-6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-carbox-
aldehyde) is a bicyclic monoterpenoid (Fig. 1). 
MATERIALS AND METHODS
Scientific databases such as PubMed, Research-
Gate, HMDB and others have been used to provide 
information on the published results of properties 
and activities of the test substance (myrtenal) over a 
period of the past 15 years (2003 – 2018). 
Sources of Myrtenal in Nature
It is found in plant species, many of which are 
typical of Bulgaria – Cuminum cyminum – 28-43.5 
=% in some varieties (20); Rosmarinus officinalis – 
5% (21); Coriandrum sativum (22); Hyssopus officina-
lis – 2.32 =% (23); Lavandula spp. – 0.1 =% (24); Ar-
temisia spp. – myrtenal combination with myrtenol 
was found to be at the highest concentrations in A. 
pontica, L, A. vulgaris, L и A. alba, L (25); Curcuma 
amada, Curcuma aromatica (26); Origanum majora-
na, Origanum vulgare (27); Helianthus annuus (28); 
Juglans regia (29); Glycirrhyza glabra; Laurus nobilis; 
Piper nigrum; Peumus boldus (30); Thymus spp. (31); 
Myrtus communis (32) and many more. Myrtenal is 
also found in essential oils of orange, lemon, pepper-
mint, juniper, ginger, parsley and others (33), as well 
as in propolis (34). 
Myrtenal-Containing Medicinal Plants and 
the Biological Activities of their Volatile Oils 
Cumminum cyminum exhibits numerous ef-
fects - antimicrobial, insecticidal, anti-inflamma-
tory, analgesic (35), antioxidant, anti-tumor, antidi-
abetic, anti-aggregative, hypotensive, bronchodila-
tor, contraceptive, etc. It affects positively osteopo-
rotic changes, amyloidogenesis, suppresses the activ-
ity of a number of enzymes and is an organoprotec-
tor (nephro-, hepato- and gastro-protector) (36). It is 
widely used as a spice in folk medicine. Fruits contain 
2.5 - 4.5% essential oil with established anti-inflam-
matory activity (37) as its main components vary ac-
cording to the geographic region. One of the major 
components of the essential oil in the Tunisian vari-
ety with antimicrobial, antimycotic and antioxidant 
activity is myrtenal (3.5%) (38). This component, iso-
lated from the plant in the region of Bulgaria, with 
no traces of myrtenal, exhibits mainly antibacterial 
effect (39). The plant‘s essential oil administered to 
mice causes a significant dose-dependent decrease in 
lipid peroxidation and elevated levels of reduced glu-
tathione, which is a prerequisite for the study of its ef-
fects on carcinogenesis (40). It also exhibits anti-ep-
ileptic properties by influencing the transmission of 
action potential in the central nervous system (CNS) 
(41). Positive effects on induced stress and memory 
stimulation of healthy and dementia rats were ob-
served in combination with decreased levels of lipid 
peroxidation (42). Cumin extract improves the lipid 
profile in rats (43) and humans (44). There was a sig-
nificant decrease in oxLDL (oxidated low-density li-
poproteins) levels in patients with hypercholesterol-
emia and an increase in paraoxonase 1 activity (with 
a protective role in the oxidation of plasma lipopro-
teins and important for atherosclerotic lesions) (45). 
The effects of Cumin cyminum in patients with di-
abetes associated with altered leptin levels, paraox-
onase 1, glycated hemoglobin, and lipid profile are 
better than vitamin E.  
Fig. 1. Chemical structure of myrtenal 
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Apart from ethnopharmacological data, the 
therapeutic potential of Rosmarinus officinalis, L. 
has long been known. Studies of plant extract and 
the essential oil show antibacterial (46), choleret-
ic, diuretic, hepatoprotective (47), anti-inflammato-
ry and analgesic (48; 49), antioxidant (50), anticolytic 
(51), antiulcerogenic (52) and anti-tumor (53) effects. 
A study of the analgesic effects of rosemary essential 
oil found that higher concentrations had better ef-
fects according to the Hot plate test and that combin-
ing it with codeine or paracetamol potentiated the 
analgesic effects (54). Rosemary essential oil, aque-
ous extract and raw plant powder enhance the activ-
ity of superoxide dismutase and total antioxidant ca-
pacity, reduce the deleterious effect of lipid peroxi-
dation in vivo on hyperlipidemic rats. The plant has 
a significant inhibitory effect on elevated serum lev-
els of total cholesterol and triglycerides, and antago-
nizes the elevated levels of lipid peroxidation induced 
by a high fat diet in vivo (55). The total plant extract 
also regulates glucose and lipid metabolism in in vi-
tro studies (56). The intraperitoneal injection of rose-
mary essential oil in mice results in a significant in-
crease in spontaneous motor activity which is indic-
ative of CNS stimulation (57). The antidepressant ef-
fects of Rosmarinus off. in acute and repetitive ad-
ministration are comparable to fluoxetine and have 
been shown to be associated with a response to se-
rotonergic, noradrenergic and dopaminergic sys-
tems (58). In a study of the effects on long-term and 
short-term memory in the oral administration of a 
water-alcoholic extract of rosemary in mice, high-
er doses demonstrated a positive influence on long-
term memory (59). In humans, essential oil (inhaled) 
produces a significant improvement in performance 
and overall memory quality but worsens the memory 
speed compared to controls (60). According to a re-
cent study, rosemary essential oil components exhib-
it antioxidant neuroprotection, positively influenc-
ing neuroinflammation and the formation of amy-
loid deposits with possible benefits in Alzheimer‘s 
disease (AD) (61). The plant extract exhibits neuro-
protective properties and affects neurodegenerative 
damage caused by oxidative stress and apoptosis ef-
fectively reducing mitochondrial membrane dam-
age and suppressing apoptosis induced by elevated 
levels of hydrogen peroxide. It also successfully de-
creases caspase activity (3 and 9) (62). It also stimu-
lates neuronal growth and and increases the levels of 
Ach (acetylcholine) similar to neuronal growth fac-
tor (NGF) in vitro with its potential use in neurode-
generative diseases (63). 
The essential oil of Lavandulla spp. has many 
biological effects - antibacterial, antifungal, carmi-
native (smooth muscle relaxing), sedative and ef-
fective for burns and insect bites. However, its pos-
sible therapeutic benefits are contradictory (64). The 
anxiolytic and antidepressant effects of the essential 
oil in inhalation (65), as well as the injection of to-
tal plant extract (66) in combination with improved 
memory functions in experimental rodents with in-
duced dementia, have recently been established.
Similar CNS effects are also observed with the 
use of α-pinene (67) as one of the main and most 
widely represented components of plant essential 
oils.
The biological properties of essential oils of 
Myrtaceae species have long been studied and are 
still being investigated (68). 
Research on the active components of Myrtus 
communis L. and their pharmacological properties 
reveals a wide range of effects - antioxidant, antican-
cer, antidiabetic, antiviral, antibacterial, antimycot-
ic, hepatoprotective and neuroprotective (69). Ex-
tracts from different parts of the plant moderately 
inhibit the activity of acetylcholinesterase, butyryl-
cholinesterase and exhibit antioxidant effects in vi-
tro (70) with the potential to influence neurodegen-
eration. According to other studies, the plant extract 
demonstrated in vitro both potent cholinesterase and 
burylesterase inhibiting properties, and it also in-
hibited lipoxygenase (71). The main compounds of 
myrtle essential oil are monoterpenoids, flavonoids 
and triterpenoids. Antimicrobial (72), antioxidant 
(73), anti-rheumatic and anti-inflammatory (68,74) 
effects of myrtle essential oil have been established. 
The anxiolytic properties of Myrtus communis es-
sential oil (75) are compared with those of diazepam. 
Better effects of the volatile oil have been identified 
than the reference, with possible mechanisms influ-
encing GABA-ergic neurotransmission. Anxiolytic 
effects have also been reported after treatment with 
the entire  complex of biologically active substances 
of the plant (76). Myrtus communis essential oil also 
prolongs barbiturate-induced sleep in mice (77). 
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Biological Effects of Bicyclic Monoterpenoid 
Myrtenal (Alone)
The observed effects typical of medicinal plants 
and their essential oils that were reported for the bi-
cyclic monoterpenoid, as well as the biological prop-
erties of α-pinene whose secondary metabolite is 
myrtenal, suggest that it is a potential carrier of some 
of the observed biological activities. 
Myrtenal, as a lipid molecule, is considered 
practically insoluble in water and relatively neu-
tral. In the cell, it is mainly located in the membrane 
(predicted according to the logP value) and the cy-
toplasm. It has a membrane-stabilizing action sup-
porting the building and maintenance of structur-
ally sound and functioning cell or organelle mem-
branes (78) .
Its metabolism data in mammals are limited 
(79; 80) and its toxicological characteristics are in-
complete (81). In plants, myrtenal is metabolical-
ly bound to α-pinene (82). In a bio-catalytic process, 
α-pinene is transformed into myrtenol with subse-
quent conversion to myrtenal (83).
In the 20th century, numerous effects of myrte-
nal in experimental animals were found - broncho-
dilatory, anti-inflammatory, anti-aggregative and 
antihemolytic (in vitro), and antibacterial (vs. G (+) 
pathogens) (84). This explains the use of plant essen-
tial oils containing myrtenal in aromatherapy in up-
per respiratory tract infections and in cardiovascu-
lar diseases (85) due to induced vasodilatation, heart 
rate reduction and hypotension in experimental con-
ditions (86). 
Antioxidant and antitumor activity of myrte-
nal has also been reported in various mechanisms 
- influencing apoptotic and pro-apoptotic signaling 
pathways, stabilizing intrinsic antioxidant protec-
tion, suppressing TNF-α (88) expression and activat-
ing suppression of tumor growth, regulating the ac-
tivity of a number of lysosomal and mitochondrial 
enzymes, influencing the processes of gluconeogen-
esis in tumor cells (71,87,89,90). The results obtained 
in our studies confirm the presence of antioxidant 
effects of myrtenal in the brain of intact laboratory 
rats (91), as well as in chemically induced dementia 
rat models (92). Oxidative status in intact laboratory 
rats’ brain demonstrated decreased SOD (superox-
ide dismutase) activity, decreased MDA (malon di-
aldehyde) levels and increased tGSH (total glutathi-
one) content in the myrtenal group compared to con-
trols. Myrtenal caused memory improvement in the 
behavioral tests and had a preventive effect on oxi-
dative damages in the brain induced by scopolamine 
– myrtenal significantly decreased MDA, increased 
the tGSH level and restored catalase (CAT) activity.
In vivo the monoterpenoid exhibits the ability 
to inactivate free radicals by suppressing colon car-
cinogenesis in Wistar rats (93) and suppressing tu-
mor progression (94). Our studies on myrtenal con-
firmed the presence of antioxidant properties in both 
intact animals and rats with induced dementia mod-
els, activating antioxidant protection by stimulating 
the activity of major endogenous enzymes, suppress-
ing lipid peroxidation levels, and increasing total glu-
tathione levels (91,92).
Myrtenal exhibits an antihyperglycemic ef-
fect in rats with a streptozotocin-induced experi-
mental diabetes mellitus model. Under these condi-
tions, myrtenal decreases plasma glucose levels, im-
proves plasma insulin levels, increases regulation of 
various glucose transporters, and subsequently im-
proves glucose utilization in the liver and skeletal 
muscles (95). Oral administration of myrtenal for 28 
days caused the following effects in animals with an 
experimental diabetes model: decreased plasma glu-
cose and hemoglobin A1c (HbA1c); increased lev-
els of insulin and hemoglobin; restored body weight; 
normalized hexokinase, glucose-6-phosphatase, 
fructose-1,6-bisphosphatase, glucose-6-phosphate 
dehydrogenase and hepatic enzymes AST, ALT and 
ALP; elevated glycogen content in the liver and mus-
cles; hepatocyte recovery; improved levels of pancre-
atic insulin and lipid profile (TC (total cholesterol), 
TG (triglycerides), phospholipids, LDL (low-density 
lipoproteins), VLDL (very low-density lipoproteins), 
atherogenic index) (96). Our experimental data con-
firm the available evidence of the ability of myrte-
nal to improve the lipid profile in intact laboratory 
rats (91). In myrtenal-treated animals a significant 
decrease in plasma levels of TC, TG and LDL along 
with increased HDL (high density lipoproteins) was 
observed. 
Myrtenal is relatively little studied in the field 
of neuroscience. The known ligand of one of the ol-
factory neurons in mammals (hVN1R1) is myrtenal 
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(EC50∼1 µM) (97). Its chemical characterization and 
its physicochemical properties (98) include an as-
sumption of its probable membrane stabilizing prop-
erties (99), and its lipophilic nature suggests its CNS 
effect due to its ability to pass the blood-brain barrier.
Our experimental studies on the CNS effects 
of myrtenal ((-)-myrtenal, 98%, purchased from 
ACRŌS Organics, Lot: A0363097) in laboratory ro-
dents have shown the potentiation of the effects of 
classical hypnotic medicines. The substance admin-
istered at a single dose significantly prolonged the 
hypnotic-sedative effects of barbiturates (Barbital so-
dium) and benzodiazepines (diazepam). These ef-
fects were likely to exhibit central mechanisms of ac-
tion and result from the interaction of myrtenal with 
the GABA receptor. Data from the literature report-
ed similar effects of newly synthesized analogues of 
myrtenal on the GABA-ergic system (100). Similar 
results for improved hypnotic effects of barbiturates 
in mice have been reported for Myrtus communis es-
sential oil and water-alcohol plant extract (101,102). 
Our data of myrtenal’s potentiating activity on clas-
sic hypnotic drugs (barbiturates) effects in combina-
tion (103) also confirm the results obtained by other 
researchers (77).
In agreement with the above-mentioned au-
thors, we believe that the mechanism of this response 
is predominately central. It is not due to metabolic 
interactions of myrtenal with barbiturates at the level 
of hepatic metabolism. In other studies of ours (103), 
myrtenal did not influence the hypnotic effect and 
metabolism of Hexobarbital sodium (a model sub-
strate of CYP450 monooxygenases). 
A probable central mechanism of action of 
myrtenal is the response to GABA neurotransmis-
sion associated with the anxiolytic properties of the 
substance. The studies of Hailu et al. (2011) found 
good anxiolytic properties of myrtle essential oil 
comparable to those of diazepam as a standard (75). 
Our studies on mice also found a significant 
anxiolytic effect of myrtenal (Marble burying test) 
comparable to that of diazepam as a reference (103). 
According to some authors, the whole complex of bi-
ologically active substances (76), like the hydroxyl 
derivative myrtenol (essential oil component), have 
anxiolytic properties (102) with possible mechanism 
of response to GABA neurotransmission.
The available scientific data as well as our own 
results give us a reason to suppose that myrtenal is 
a potential carrier of these pharmacological effects. 
This is also confirmed by the reported anxiolytic 
activity of synthesized myrtenal analogues in mice 
(100). The same authors found that the main mech-
anism of action is influencing the GABA- as well as 
the DA-ergic system in rodents. 
There is still limited data in the literature on the 
effects of myrtenal on the major brain neurotransmit-
ters levels. The reported inhibitory effects of myrte-
nal on acetylcholinesterase activity in vitro (104) have 
not been confirmed in in vivo experiments, including 
in our own experiments on mice (105).
Neuromodulatory activity of myrtenal was es-
tablished after its repeated (14 days) administration 
in laboratory rats. Myrtenal significantly increased 
the levels of three major mediators in the brains – 
acetylcholine (ACh), 5-hydroxytriptamine (5-HT) 
and dopamine (DA) in comparison to controls. 
These data were confirmed by better performance 
of myrtenal-treated rodents in memory and learning 
status than in controls (106). We assume that the ob-
served central effects of myrtenal were probably due 
to the lipophilic nature of its molecule, which deter-
mines a better distribution in the CNS (78).  
Despite the reported myrtenal acetylcholines-
terase activity inhibiting effects in vitro to warrant 
the authors suggesting its ability to affect memory in 
experimental dementia, data on its effects on animal 
models of neurodegeneration were not found in the 
literature. 
Our studies have found pronounced improve-
ment effects of myrtenal (in single and multiple ap-
plication) on memory and learning in rodents with 
experimental (scopolamine-induced) dementia 
(107) associated with the neuromodulatory action 
of myrtenal. Compared to controls, elevated levels 
of major brain neurotransmitters – noradrenaline 
(NA), DA, ACh and 5-HT, in the brain of mytenal-
treated animals were observed. 
The preventive effect of myrtenal on the course 
of the neurodegenerative process was confirmed in 
our other studies in rats with an experimental model 
(6-OHDA-induced) of Parkinson‘s disease (PD). De-
layed course of disease, improved motor coordina-
tion and improved cognitive function were observed 
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compared to untreated rats with PD. These results 
were accompanied by preserved levels of dopamine 
in the brains of myrtenal-treated rats in comparison 
to 6-OHDA control rats (unpublished data).
In addition to the presence of neuromodulatory 
activity of myrtenal, significant antioxidant effects 
were detected in ICR mice and Wistar rats with neu-
rodegenerative disease models (AD and PD). Myrte-
nal caused memory improvement in the behavioral 
tests and had a positive effect on altered oxidative sta-
tus induced by scopolamine - decreased MDA and 
increased tGSH level, as well as restored CAT activity 
in the animal’s brain. Obviously, the established neu-
roprotective effects of myrtenal are due to its com-
plex mechanisms of action, both neuromodulatory 
and antioxidant ones (108,109).
CONCLUSION 
Significant improving effects of myrtenal on 
memory and learning in experimental rodents, as 
well as its protective effects on neurodegenerative 
processes are established. Probably they are related to 
its complex mechanisms of action. At least two mech-
anisms are involved in the established protecting ef-
fects of myrtenal on the neurodegenerative processes 
- neuromodulatory and antioxidant but they deserve 
more detailed studies.
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